The overall goal of the MeritCare Hospital CCOP is to provide state-of- the-art cancer care to patients and families as close to home as possible through participation in NCI approved clinical trials. The MeritCare Hospital CCOP proposes to refine and expand its existing cancer treatment and control research program.
Specific Aims and Methods of this Proposal are: 1. Increase the number of eligible patients placed on approved cancer treatment and cancer control research protocols through affiliation with cooperative research group. The CCOP will accomplish this through its affiliation with NCCTG and three secondary research bases,ECOG, NSABP, and CCG. 2. Continue to enhance the participation of primary health providers and other specialists along with the CCOP investigators in cancer treatment and control research. The CCOP will continue to strengthen its ties with the MeritCare and CCOP network physician practices via outreach, enhanced communication and education. 3. Foster the recruitment of minority populations in the CCOP referral area to clinical trials. Although the minority populations are relatively small, the CCOP will seek to establish ties with physicians who are in contact with the minority population in our service area. The CCOP will continue participation in the Breast Cancer Prevention Trial. 4. Enhance the quality of the data management. Strengthen the data management system by increased computerization, quality assurance screening all new patient charts for eligibility for clinical trials and refinement of the current data management systems. 5. Provide cancer control programs for regional health care professionals and the general public. The CCOP will accomplish this goal via breast, prostate and skin screenings as well as cancer related education programs for nurses, physicians and other health care professionals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037417-15
Application #
2712588
Study Section
Special Emphasis Panel (SRC (74))
Program Officer
Dunn, Barbara K
Project Start
1983-09-30
Project End
1999-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Roger Maris Cancer Center
Department
Type
DUNS #
City
Fargo
State
ND
Country
United States
Zip Code
58103
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27

Showing the most recent 10 out of 136 publications